Aethlon Medical (NASDAQ: AEMD) Research/Media Alert: "Expect Focus on Oncology Studies; Cost Containment Efforts"
Aethlon Medical (NASDAQ: AEMD) Research/Media Alert: Expect Focus on Oncology Studies; Cost Containment Efforts
Stay updated with breaking news from Drug Controller General. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aethlon Medical (NASDAQ: AEMD) Research/Media Alert: Expect Focus on Oncology Studies; Cost Containment Efforts
Likewise, Central Drugs Testing Laboratory (CDTL) Mumbai analysed 523 samples, out of which 18 samples from 10 firms failed quality tests. Regional Drugs Testing Laboratory (RDTL) Chandigarh released 284 test reports, and 23 samples from 10 firms were NSQ. Indian Pharmacopoeia Commission (IPC) Ghaziabad released 502 reports, out of which 29 from nine firms failed the quality test.
India Coronary Stent IndustryThe adoption of global india coronary stent industry size is likely to jump from US$ 843.8 million in 2023 to US$ 1,213.5 million by 2033. This projected expansion is anticipated to result from an average 3.7% CAGR in the demand for coronary stents in India over the upcoming decade.Cardi...
In India, issues related to access and safety of blood have emerged time and again. This issue is particularly concerning in the case of repeat blood recipients like patients of blood transfusion...
India has more than 37 million individuals struggling with COPD